IMVT Quote, Financials, Valuation and Earnings

Nutriband, Inc. has a net margin of -- compared to Immunovant, Inc.'s net margin of -1118.87%. Immunovant, Inc.'s return on equity of -73.12% beat Nutriband, Inc.'s return on equity of -164.64%.

Immunovant, Inc. has a consensus price target of $40.63, signalling upside risk potential of 56.61%. On the other hand Nutriband, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 248.03%. Given that Nutriband, Inc. has higher upside potential than Immunovant, Inc., analysts believe Nutriband, Inc. is more attractive than Immunovant, Inc..

Immunovant, Inc. has a beta of 0.541, which suggesting that the stock is 45.89% less volatile than S&P 500. In comparison Nutriband, Inc. has a beta of 1.886, suggesting its more volatile than the S&P 500 by 88.601%.

Immunovant, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunovant, Inc. pays -- of its earnings as a dividend. Nutriband, Inc. pays out -- of its earnings as a dividend.

Immunovant, Inc. quarterly revenues are --, which are smaller than Nutriband, Inc. quarterly revenues of $346.1K. Immunovant, Inc.'s net income of -$110.6M is lower than Nutriband, Inc.'s net income of -$3.9M. Notably, Immunovant, Inc.'s price-to-earnings ratio is -- while Nutriband, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunovant, Inc. is -- versus 21.51x for Nutriband, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -- compared to Immunovant, Inc.'s net margin of -316.61%. Immunovant, Inc.'s return on equity of -73.12% beat Plus Therapeutics, Inc.'s return on equity of --.

Immunovant, Inc. has a consensus price target of $40.63, signalling upside risk potential of 56.61%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1928.02%. Given that Plus Therapeutics, Inc. has higher upside potential than Immunovant, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Immunovant, Inc..

Immunovant, Inc. has a beta of 0.541, which suggesting that the stock is 45.89% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

Immunovant, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunovant, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Immunovant, Inc. quarterly revenues are --, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Immunovant, Inc.'s net income of -$110.6M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Immunovant, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunovant, Inc. is -- versus 4.35x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Revvity, Inc. has a net margin of -- compared to Immunovant, Inc.'s net margin of 12.41%. Immunovant, Inc.'s return on equity of -73.12% beat Revvity, Inc.'s return on equity of 3.2%.

Immunovant, Inc. has a consensus price target of $40.63, signalling upside risk potential of 56.61%. On the other hand Revvity, Inc. has an analysts' consensus of $119.56 which suggests that it could grow by 18.26%. Given that Immunovant, Inc. has higher upside potential than Revvity, Inc., analysts believe Immunovant, Inc. is more attractive than Revvity, Inc..

Immunovant, Inc. has a beta of 0.541, which suggesting that the stock is 45.89% less volatile than S&P 500. In comparison Revvity, Inc. has a beta of 1.066, suggesting its more volatile than the S&P 500 by 6.609%.

Immunovant, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revvity, Inc. offers a yield of 0.28% to investors and pays a quarterly dividend of $0.07 per share. Immunovant, Inc. pays -- of its earnings as a dividend. Revvity, Inc. pays out 13.61% of its earnings as a dividend. Revvity, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Immunovant, Inc. quarterly revenues are --, which are smaller than Revvity, Inc. quarterly revenues of $772.1M. Immunovant, Inc.'s net income of -$110.6M is lower than Revvity, Inc.'s net income of $95.8M. Notably, Immunovant, Inc.'s price-to-earnings ratio is -- while Revvity, Inc.'s PE ratio is 48.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunovant, Inc. is -- versus 4.13x for Revvity, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viridian Therapeutics, Inc. has a net margin of -- compared to Immunovant, Inc.'s net margin of -49.03%. Immunovant, Inc.'s return on equity of -73.12% beat Viridian Therapeutics, Inc.'s return on equity of -47.79%.

Immunovant, Inc. has a consensus price target of $40.63, signalling upside risk potential of 56.61%. On the other hand Viridian Therapeutics, Inc. has an analysts' consensus of $42.06 which suggests that it could grow by 39.87%. Given that Immunovant, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Immunovant, Inc. is more attractive than Viridian Therapeutics, Inc..

Immunovant, Inc. has a beta of 0.541, which suggesting that the stock is 45.89% less volatile than S&P 500. In comparison Viridian Therapeutics, Inc. has a beta of 0.962, suggesting its less volatile than the S&P 500 by 3.833%.

Immunovant, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viridian Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immunovant, Inc. pays -- of its earnings as a dividend. Viridian Therapeutics, Inc. pays out -- of its earnings as a dividend.

Immunovant, Inc. quarterly revenues are --, which are smaller than Viridian Therapeutics, Inc. quarterly revenues of $70.6M. Immunovant, Inc.'s net income of -$110.6M is lower than Viridian Therapeutics, Inc.'s net income of -$34.6M. Notably, Immunovant, Inc.'s price-to-earnings ratio is -- while Viridian Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immunovant, Inc. is -- versus 34.49x for Viridian Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.